Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Blocking NO synthesis: how, where and why?

Patrick Vallance1, James Leiper

  • 1Centre for Clinical Pharmacology, British Heart Foundation Laboratories, Department of Medicine, University College London, 5 University Street, London WC1E 6JJ, UK. patrick.wallance@ucl.ac.uk

Nature Reviews. Drug Discovery
|December 4, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

British Heart Foundation Data Science Centre 2.0: faster, fairer cardiovascular data-driven discovery.

European heart journal·2026
Same author

Temporal motor evoked potential decomposition reveals that cortico-reticulospinal excitability is increased in athletes with patellar tendinopathy - Preliminary evidence of compensatory adaptation for diminished motor drive.

Journal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology·2026
Same author

Greater endogenous pain facilitation is associated with lower spinal excitability and maximal knee extension strength deficits in athletes with patellar tendinopathy.

European journal of applied physiology·2026
Same author

Neural deficits relevant to pain symptoms and functional impairments in individuals with Achilles or patellar tendinopathy (PhD Academy Award).

British journal of sports medicine·2025
Same author

Transcranial magnetic stimulation and electrical stimulation techniques used to measure the excitability of distinct neuronal populations that influence motor output in people with persistent musculoskeletal conditions: A scoping review and narrative synthesis of evidence.

Journal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology·2025
Same author

Response letter: The only defendable scientific position: A strong case against radial extracorporeal shockwave therapy for insertional Achilles tendinopathy.

Clinical rehabilitation·2025
Same journal

HuR degrader knocks down BRAF in cancer.

Nature reviews. Drug discovery·2026
Same journal

R&D productivity trends for biopharma companies in Asia and emerging markets.

Nature reviews. Drug discovery·2026
Same journal

Growth in clinical research capability in China and impact on the pharmaceutical sector.

Nature reviews. Drug discovery·2026
Same journal

Circular RNA guides exon skipping in DMD.

Nature reviews. Drug discovery·2026
Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026
Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026
See all related articles

Researchers are developing drugs to reduce nitric oxide (NO) synthesis, a key mediator implicated in various diseases. This approach aims to address challenges in pharmacologically modulating NO levels for therapeutic benefit.

Area of Science:

  • Physiology
  • Pharmacology
  • Drug Development

Background:

  • Nitric oxide (NO) is a critical physiological mediator.
  • Disordered NO generation is linked to numerous pathological conditions.
  • Modulating NO levels presents therapeutic opportunities and challenges.

Purpose of the Study:

  • To explore the rationale for reducing NO synthesis.
  • To evaluate the potential of pharmacological approaches targeting NO reduction.
  • To introduce compounds developed for decreasing NO synthesis.

Main Methods:

  • Focus on strategies to inhibit NO synthesis.
  • Development of novel compounds targeting NO production pathways.
  • Pre-clinical evaluation of NO-reducing agents.

Related Experiment Videos

Main Results:

  • Identification of promising therapeutic targets for NO modulation.
  • Development of several compounds designed to reduce NO synthesis.
  • Compounds are advancing towards clinical trials.

Conclusions:

  • Reducing NO synthesis is a viable therapeutic strategy.
  • Pharmacological interventions targeting NO reduction show promise.
  • New compounds offer potential treatments for NO-related pathologies.